Pre-surgery combo for advanced gastroesophageal junction cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs—tislelizumab (immunotherapy), anlotinib (targeted therapy), and a chemotherapy regimen (S1 plus oxaliplatin)—given before surgery for locally advanced adenocarcinoma of the gastroesophageal junction. The goal is to see if this approach can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of cancer called adenocarcinoma of the gastroesophageal junction (Siewert type II or III) that is locally advanced but can be surgically removed.
- Your daily activity level is good (ECOG score 0 or 1).
- You have not had any prior surgery, chemotherapy, radiation, or immunotherapy for this cancer.
- Your cancer is not HER2 positive.
- You have no major bleeding problems, recent heart or blood vessel issues, or intestinal blockage.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy to shrink gastroesophageal junction cancer before surgery. It aims to make the tumor removable and improve outcomes.
This trial tests a combination of shortened radiation therapy, immunotherapy, and chemotherapy given before surgery for cancer at the junction of the esophagus and stomach. The goal is to see if this approach is safe and improves outcomes.
This trial tests a new combination (tislelizumab plus apatinib and chemotherapy) before surgery for certain advanced stomach cancers, compared with the standard chemotherapy plus S1. The goal is to shrink the tumor and improve outcomes before and around surgery.
This trial tests a combination of chemotherapy (FLOT), an immunotherapy drug (pembrolizumab), and short-course radiation before surgery for gastroesophageal junction cancer. The goal is to see if this approach improves outcomes.
This trial tests giving an immunotherapy drug (adebrelimab) along with two chemotherapy drugs (capecitabine and oxaliplatin) before and after surgery for a specific type of stomach-cancer junction tumor. It aims to see if this combination is safe and effective in shrinking the tumor and improving outcomes.
This trial tests a new combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX) given before surgery for locally advanced gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors more effectively.
Hear when a new Immunotherapy Gastroesophageal Junction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.